Blood Component Separation: Centrifugation, Apheresis, and Advanced Techniques

Centrifugation: The Foundation of Component Separation

Centrifugation remains the cornerstone of blood processing. Whole blood is spun at high speed, separating into three distinct layers: red blood cells (RBCs) settle at the bottom, a thin buffy coat containing platelets and white blood cells forms in the middle, and plasma rises to the top. Two spin protocols are standard: a hard spin yields packed RBCs and plasma, while a soft spin produces platelet-rich plasma (PRP) and RBCs. Automated separators such as the Trima and Alyx systems have standardized this process, ensuring consistent component quality and volume.

Apheresis: Donor-Specific Collection

Apheresis uses continuous-flow cell separators to collect a specific blood component directly from the donor while returning the remaining elements. This technique yields high-dose products—single-donor platelets equivalent to 6–8 pooled units, double red cell units (2RBC), plasma, granulocytes, and peripheral blood stem cells (PBSCs). Advantages include higher component yield, reduced donor exposure for recipients, and the ability to tailor inventory to clinical demand.

Filtration: Leukoreduction and Beyond

Filtration plays a critical role in component safety. Prestorage leukoreduction filters remove white blood cells to fewer than 5×10⁶ per unit, significantly lowering the risk of HLA alloimmunization, cytomegalovirus (CMV) transmission, and febrile non-hemolytic transfusion reactions (FNHTR). Platelet-rich plasma filtration and microaggregate filters (now less common) address other quality aspects.

Cryoprecipitation: Harvesting High-Value Proteins

Fresh frozen plasma (FFP) thawed at 1–6°C forms a precipitate rich in Factor VIII, von Willebrand factor (vWF), fibrinogen, and Factor XIII. Centrifugation separates this cryoprecipitate (cryo) from cryo-poor plasma. Cryo is a targeted therapy for fibrinogen replacement, von Willebrand disease, and disseminated intravascular coagulation (DIC).

Immunoaffinity Chromatography: Purifying Specific Factors

This method isolates individual plasma proteins—such as Factor VIII, Factor IX, protein C, and intravenous immunoglobulin (IVIG)—using ligand-specific binding, elution, viral inactivation, and concentration. While historically vital, recombinant factor products have largely supplanted plasma-derived concentrates for many indications.

Pathogen Reduction: An Added Safety Layer

Technologies like INTERCEPT (amustaline + UVA), Mirasol (riboflavin + UV), and solvent/detergent treatment for plasma provide an additional safeguard against infectious agents, further enhancing the safety of transfusable components.

Quality Assurance: From Vein to Vein

Rigorous component specifications—volume, cell count, pH, sterility—are mandated by AABB and FDA standards. Full traceability from donor to recipient ensures accountability and enables rapid response to any adverse event.

Blood Disorders - Related Articles